IMM01

Phase 3Biologic

IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

IMM01 is one of 124 biologic programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Chronic Myelomonocytic LeukemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Chronic Myelomonocytic LeukemiaPhase 3

Active, not recruiting

Myelodysplastic SyndromePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

IMM01

IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 3

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Velban

EEastern Cooperative Oncology Group

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Norvir

AbbVie

Preclinical

1 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 8

Tafasitamab

Incyte

Preclinical

7 9

Nuvigil

NNuvo Research GmbH

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

Lymphoma

NCT06465446

Phase 1/2Not yet recruiting

Patients With Advanced Solid Tumors

NCT07170787

Q4 2029

Phase 3Recruiting

Chronic Myelomonocytic Leukemia

NCT06647862

Clinical

Trials by Indication[1]

Lymphoma2 trials

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 3·NCT06465446·202 enrolled

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Unknown status·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1/2·NCT05833984·309 enrolled

Recurrent Hematologic Malignancy1 trial

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Terminated·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1·NCT05860075·73 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1/2·NCT07170787·104 enrolled

Myelodysplastic Syndrome1 trial

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Unknown status·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1/2·NCT05140811·126 enrolled

Chronic Myelomonocytic Leukemia1 trial

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 3·NCT06647862·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for IMM01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMM01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMM01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmuneOnco Biopharmaceuticals (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

IMM01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2029

Trials by Indication[1]

Lymphoma2 trials

Recurrent Hematologic Malignancy1 trial

Patients With Advanced Solid Tumors1 trial

Myelodysplastic Syndrome1 trial

Chronic Myelomonocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News